[Treatment of chronic cystitis in postmenopausal women].
A randomized double blind controlled trial of intravaginal cream ovestin (estriol) was conducted in 102 postmenopausal females with chronic cystitis. The patients were divided into two groups. Group 1 (n = 52) received standard therapy, group 2 (n = 50) received standard therapy plus ovestin (daily intravaginal administration for 2 weeks, then twice a week). Final results were evaluated 1 year after therapy. Before the treatment 94% patients had subnormal levels of blood estradiol. One year after the treatment positive results were achieved in 91.3% patients of group 2 and 65.8% of group 1 (p < 0.001). In group 2 patients ovestin significantly reduced pollakiuria, nocturia, episodes of urgent urinary incontinence, painful voiding. Percentage of patients with leukocyturia diminished from 100 to 8%, bacteriuria--from 74 to 4%, with vaginal lactobacilli increased from 0 to 56%, enterobacterial contamination of the vagina fell from 66 to 12%. Vaginal pH decreased from 6.0 to 3.6. Addition of ovestin to standard therapy reduced the number of cystitis recurrences 11-fold, days of antibacterial therapy--12.4-fold. Side effects of ovestin (vaginal pruritus) were seen in 4% patients.
Davidov
M I
MI
Petruniaev
A I
AI
Bunova
N E
NE
D000282:Administration, Intravaginal; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D003556:Cystitis / Q000188:drug therapy* / Q000382:microbiology / Q000652:urine; D004311:Double-Blind Method; D004964:Estriol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008875:Middle Aged; D053158:Nocturia / Q000188:drug therapy / Q000382:microbiology / Q000652:urine; D017698:Postmenopause; D014549:Urinary Incontinence / Q000188:drug therapy / Q000382:microbiology / Q000652:urine
D004964:Estriol